Add to ORKGThe paper reviews developments in the EU competition practice approach to “reverse payment agreements”. These are settlements that involve a payment (in direct or indirect form) flowing in a direction that intuitively appears “reverse”, as money is paid by the patent holder (the originator) to the alleged infringer – a generic firm
Although brand-name pharmaceutical companies routinely procure patents on their innovative medicatio...
Reverse payment settlements have ignited a firestorm debate among all affected parties: consumer gro...
Paragraph IV of the Hatch-Waxman Act provides a mechanism for litigating pharmaceutical patent infri...
The paper reviews developments in the EU competition practice approach to “reverse payment agreement...
Within the tool-box developed by originator companies in order to prepare and respond to generic en...
The aim of the paper is to analyse the issue of reverse payment agreements concluded in a context of...
The aim of the paper is to analyse the issue of reverse payment agreements concluded in a context of...
This thesis focuses on so-called “reverse payment patent settlements” or “pay-for-delay settlements”...
On 17 January 2011, the European Commission launched , a monitoring exercise of patent settlements i...
Reverse payments are payments that are made as a component of a patent infringement settlement, betw...
The term reverse payment has been used as shorthand to characterize a variety of diverse agreement...
This presentation addresses the question of how patent settlements should be treated under EU compet...
Reverse payment settlements in pharmaceutical patent litigation, also known as pay for delay settl...
Pharmaceutical companies spend much of their time and resources in conducting clinical trials for de...
Several federal courts of appeal have recently ruled on the issue of whether a pharmaceutical patent...
Although brand-name pharmaceutical companies routinely procure patents on their innovative medicatio...
Reverse payment settlements have ignited a firestorm debate among all affected parties: consumer gro...
Paragraph IV of the Hatch-Waxman Act provides a mechanism for litigating pharmaceutical patent infri...
The paper reviews developments in the EU competition practice approach to “reverse payment agreement...
Within the tool-box developed by originator companies in order to prepare and respond to generic en...
The aim of the paper is to analyse the issue of reverse payment agreements concluded in a context of...
The aim of the paper is to analyse the issue of reverse payment agreements concluded in a context of...
This thesis focuses on so-called “reverse payment patent settlements” or “pay-for-delay settlements”...
On 17 January 2011, the European Commission launched , a monitoring exercise of patent settlements i...
Reverse payments are payments that are made as a component of a patent infringement settlement, betw...
The term reverse payment has been used as shorthand to characterize a variety of diverse agreement...
This presentation addresses the question of how patent settlements should be treated under EU compet...
Reverse payment settlements in pharmaceutical patent litigation, also known as pay for delay settl...
Pharmaceutical companies spend much of their time and resources in conducting clinical trials for de...
Several federal courts of appeal have recently ruled on the issue of whether a pharmaceutical patent...
Although brand-name pharmaceutical companies routinely procure patents on their innovative medicatio...
Reverse payment settlements have ignited a firestorm debate among all affected parties: consumer gro...
Paragraph IV of the Hatch-Waxman Act provides a mechanism for litigating pharmaceutical patent infri...